The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum. (Q39494589)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1 reference

Cryptosporidium parvum

object named as

Cryptosporidium parvum

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Barbara Ruozi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Flavio Forni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Maria Angela Vandelli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

L Bondioli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

A Ludovisi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

E Pozio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M A Gómez-Morales

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

8 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1384-1391

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819637%20AND%20SRC:MED&resulttype=core&format=json

Nanoparticle-cell interactions: drug delivery implications

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

Drug treatment and novel drug target against Cryptosporidium

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Antiretroviral medications: adverse effects on the kidney

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Treatment of cryptosporidiosis in immunocompromised hosts.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Early Antiretroviral Therapy and Mortality among HIV-Infected Infants

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Genetic polymorphism in Cryptosporidium species: an update.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Microencapsulation of ovalbumin in poly(lactide-co-glycolide) by an oil-in-oil (o/o) solvent evaporation method

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Polymeric nanoparticles for the drug delivery to the central nervous system

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Cryptosporidiosis in children in Sub-Saharan Africa: a lingering challenge

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Modulation of nucleic acid structure by ligand binding: induction of a DNA.RNA.DNA hybrid triplex by DAPI intercalation.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Multifunctional nanocarriers

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Brain drug delivery of small molecules using immunoliposomes

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

The impact of HIV-protease inhibitors on opportunistic parasites

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Antiretroviral therapy of late presenters with advanced HIV disease

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Absence of weight loss during Cryptosporidium infection in susceptible mice deficient in Fas-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

A theoretical model of erosion and macromolecular drug release from biodegrading microspheres

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Therapeutic nanoparticles for drug delivery in cancer

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

A foodborne outbreak of Cryptosporidium hominis infection.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Surface-engineered nanoparticles for multiple ligand coupling

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Multifunctional nanoparticles--properties and prospects for their use in human medicine.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Biofunctionalized targeted nanoparticles for therapeutic applications

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Health Sequelae of Human Cryptosporidiosis in Immunocompetent Patients

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Prophylaxis with tercef of infection-related complications after cesarean section

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021

Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking

1 reference

https://api.crossref.org/works/10.1017%2FS0031182011001119

7 January 2021